0
0
1/6/23 at 9:00am
Organization
EIN News
47 words
0
Comments
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023 Stelara® (ustekinumab) is prescribed
You are the first to view
https://www.einnews.com/pr_news/609849159/alvotech-and-teva-announce-acceptance-of-u-s-biologics-license-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab
Create an account
or login to join the discussion